RAGE Genetic Polymorphisms Are Associated with Risk, Chemotherapy Response and Prognosis in Patients with Advanced NSCLC

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Wang, Xiang ^a   Cui, Enhai ^a   Zeng, Huazong ^b   Hua, Feng ^a   Wang, Bin ^a   Mao, Wei ^a   Feng, Xueren ^a  

^a HUZHOU CENTRAL HOSPITAL   (China)

^b TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PEMETREXED; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; HYPERTHERMIC THERAPY; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACOGENETICS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RAGE GENE; TREATMENT RESPONSE;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, IMMUNOLOGIC;

EID: 84867183651     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043734     Document Type: Article

References (32)

1. Rosell R, Cobo M, Isla D, Sanchez JM, Taron M, et al. (2005) Applications of genomics in NSCLC. Lung Cancer 50 (Suppl 2):: S33-40.
2. Pathak AK, Bhutani M, Mohan A, Guleria R, Bal S, et al. (2004) Non small cell lung cancer (NSCLC): current status and future prospects. Indian J Chest Dis Allied Sci 46: 191-203.
3. Okamoto H, Watanabe K, (2007) [Medical treatment for stage III non-small-cell lung cancer (NSCLC)]. Gan To Kagaku Ryoho 34: 841-848.
4. Brockmoller J, Junker K, Multhoff G, (2006) [New perspectives in the management of non-small-cell lung carcinoma (NSCLC)]. Onkologie 29 (Suppl 2):: 25-28.
5. Chang A, (2011) Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 71: 3-10.
6. Gautschi O, Hugli B, Ziegler A, Bigosch C, Bowers NL, et al. (2006) Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. Lung Cancer 51: 303-311.
7. Zhou C, Ren S, Zhou S, Zhang L, Su C, et al. (2010) Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Jpn J Clin Oncol 40: 954-960.
8. Cui LH, Yu Z, Zhang TT, Shin MH, Kim HN, et al. (2011) Influence of polymorphisms in MTHFR 677 C→T, TYMS 3R→2R and MTR 2756 A→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC. Pharmacogenomics 12: 797-808.
9. Sterenczak KA, Willenbrock S, Barann M, Klemke M, Soller JT, et al. (2009) Cloning, characterisation, and comparative quantitative expression analyses of receptor for advanced glycation end products (RAGE) transcript forms. Gene 434: 35-42.
10. Logsdon CD, Fuentes MK, Huang EH, Arumugam T, (2007) RAGE and RAGE ligands in cancer. Curr Mol Med 7: 777-789.
11. Buckley ST, Ehrhardt C, (2010) The receptor for advanced glycation end products (RAGE) and the lung. J Biomed Biotechnol 2010: 917108.
12. Bartling B, Hofmann HS, Weigle B, Silber RE, Simm A, (2005) Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis 26: 293-301.
13. Jing R, Cui M, Wang J, Wang H, (2010) Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer. Neoplasma 57: 55-61.
14. Dabritz J, Friedrichs F, Weinhage T, Hampe J, Kucharzik T, et al. (2011) The functional -374T/A polymorphism of the receptor for advanced glycation end products may modulate Crohn's disease. Am J Physiol Gastrointest Liver Physiol 300: G823-832.
15. Picheth G, Heidemann M, Pedrosa FO, Chautard-Freire-Maia EA, Costantini CO, et al. (2007) The -429 T>C polymorphism of the receptor for advanced glycation end products (RAGE) is associated with type 1 diabetes in a Brazilian population. Clin Chim Acta 383: 163-164.
16. Jang Y, Kim JY, Kang SM, Kim JS, Chae JS, et al. (2007) Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans. Metabolism 56: 199-205.
17. Gu H, Yang L, Sun Q, Zhou B, Tang N, et al. (2008) Gly82Ser polymorphism of the receptor for advanced glycation end products is associated with an increased risk of gastric cancer in a Chinese population. Clin Cancer Res 14: 3627-3632.
18. Krechler T, Jachymova M, Mestek O, Zak A, Zima T, et al. (2010) Soluble receptor for advanced glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer. Clin Biochem 43: 882-886.
19. Tesarova P, Kalousova M, Jachymova M, Mestek O, Petruzelka L, et al. (2007) Receptor for advanced glycation end products (RAGE)-soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest 25: 720-725.
20. Wu KH, Cui B, Yu CT, Liu YL, (2006) Stem cells: new cell source for myocardial constructs tissue engineering. Med Hypotheses 67: 1326-1329.
21. Yin YM, Geng YT, Shao YF, Hu XL, Li W, et al. (2010) First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer. J Exp Clin Cancer Res 29: 126.
22. Santo A, Genestreti G, Terzi A, Azzoni P, Sava T, et al. (2006) Gemcitabine (GEM) and vindesine (VDS) in advanced non-small cell lung cancer (NSCLC): a phase II study in elderly or poor performance status patients. Lung Cancer 53: 355-360.
23. Kim SO, Jeong JY, Kim MR, Cho HJ, Ju JY, et al. (2008) Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin Cancer Res 14: 3083-3088.
24. Shi YY, He L, (2005) SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15: 97-98.
25. Gaens KH, Ferreira I, van der Kallen CJ, van Greevenbroek MM, Blaak EE, et al. (2009) Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels. J Clin Endocrinol Metab 94: 5174-5180.
26. Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, et al. (2002) RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 3: 123-135.
27. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, et al. (2002) Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 196: 163-170.
28. Fuentes MK, Nigavekar SS, Arumugam T, Logsdon CD, Schmidt AM, et al. (2007) RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis Colon Rectum 50: 1230-1240.
29. KimCurran V, Zhou C, Schmid-Bindert G, Shengxiang R, Zhou S, et al. (2011) Lack of correlation between ERCC1 (C8092A) single nucleotide polymorphism and efficacy/toxicity of platinum based chemotherapy in Chinese patients with advanced non-small cell lung cancer. Adv Med Sci 56: 30-38.
30. Feng J, Sun X, Sun N, Qin S, Li F, et al. (2009) XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer. Acta Biochim Biophys Sin (Shanghai) 41: 429-435.
31. Han JY, Lee GK, Jang DH, Lee SY, Lee JS, (2008) Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer 113: 799-807.
32. Li D, Zhou Q, Liu Y, Yang Y, Li Q, (2011) DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy. Med Oncol.